The International Generic and Biosimilar medicines Association (IGBA) today released a report identifying key factors affecting the security of the global supply of generic prescription medicines.
The International Generic and Biosimilar Medicines Association is an international organization of national and regional associations representing manufacturers of generic and biosimilar medicines from around the world. Our industry supplies an estimated 80% of all quality-assured medicines globally and is therefore absolutely critical to ensuring safe and affordable medicines are available to patients worldwide and indispensable for achieving Universal Health Coverage.
Fight the Fakes Alliance calls for a watertight global medicines supply chain.
- IGBA Reiterates its Yearly Call to Join the Biosimilars Movement on Advancing Access (November 2022)
- IGBA’s CEO Advisory Committee Meets with WHO Director General and WHO Leadership (October 2022)
- Richard Saynor and Vinita Gupta appointed Chair and Vice-Chair of IGBA CEO Advisory Committee (October 2022)
- Global Biosimilars Week: Message of Vivian Frittelli, Chair, IGBA (October 2022)
